

## **Implant removal after internal fixation of a femoral neck fracture: effects on physical functioning**

Stephanie M. Zielinski<sup>1</sup>, Martin J. Heetveld<sup>2</sup>, Mohit Bhandari<sup>3</sup>, Peter Patka<sup>4</sup>, Esther M.M. Van Lieshout<sup>1</sup>, on behalf of the FAITH trial investigators\*

<sup>1</sup> Trauma Research Unit Department of Surgery, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands

<sup>2</sup> Dept. of Surgery, Kennemer Gasthuis, P.O. Box 417, 2000 AK, Haarlem, the Netherlands

<sup>3</sup> Dept. of Clinical Epidemiology and Biostatistics, McMaster University, HSC 2C, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada

<sup>4</sup> Dept. of Emergency Medicine, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands

Corresponding author:

E.M.M. van Lieshout, MSc PhD

Erasmus MC, University Medical Center Rotterdam

Trauma Research Unit Department of Surgery

P.O. Box 2040

3000 CA Rotterdam

The Netherlands

Phone: +31.10.7031050 / Fax: +31.10.7032396

E-mail: [e.vanlieshout@erasmusmc.nl](mailto:e.vanlieshout@erasmusmc.nl)

## **Acknowledgements**

FAITH trial study group:

*Steering Committee:* Mohit Bhandari (Chair), Marc Swiontkowski, PJ Devereaux, Gordon Guyatt, Martin J. Heetveld, Kyle Jeray, Susan Liew, Emil H. Schemitsch, Lehana Thabane, Stephen Walter

*Global Methods Centre:* Mohit Bhandari (Principal Investigator); Sheila Sprague (Research Program Manager); Helena Viveiros, *Paula McKay*, Taryn Scott, Marilyn Swinton, (Research Coordination); Victoria Truong and Kaitlin Koo (Adjudication Coordination); Diane Heels-Ansdell, Qi Zhou (Statistical Analysis); Lisa Buckingham, Aravin Duraikannan (Data Management); Deborah Maddock, Nicole Simunovic (Grant Management) (**McMaster University**)

*US Methods Centre:* Marc Swiontkowski (Principal Investigator); Julie Agel (Research Coordination) (**University of Minnesota**)

*Netherlands Method Centre:* Martin J. Heetveld (Principal Investigator); Esther M.M. Van Lieshout (Research Coordination); Stephanie M. Zielinski (Trial Coordination) (**Erasmus MC, University Medical Center Rotterdam**)

*UK Method Centre:* Amar Rangan (Principal Investigator), Birgit C. Hanusch, Lucksy Kottam, Rachel Clarkson (Research Coordination) (**The James Cook University Hospital**)

*Central Adjudication Committee:* Gregory J Della Rocca (Chair), Robert Haverlag, Susan Liew, Gerard Slobogean

*Data Safety Monitoring Board:* Jeffrey Katz (Chair), Brenda Gillespie, Gail A. Greendale, Pierre Guy, Curtis Hartman, Craig Rubin, James Waddell

## **Clinical Site Investigators**

The following persons participated in the FAITH Study:

*Canada:*

Robert McCormack, Kelly Apostle, Dory Boyer, Farhad Moola, Bertrand Perey, Trevor Stone, Darius Viskontas and H. Michael Lemke, Mauri Zomar, Karyn Moon, Raely Moon, Amber Oatt (**University of British Columbia/Fraser Health Authority**); Richard E. Buckley, Paul Duffy, Robert Korley, Shannon Puloski, Kelly Johnston, James Powell, Kimberly Carcary (**Foothills Medical Centre**); David Sanders, Abdel Lawendy, Christina Tieszer (**London Health Sciences Centre**); David Stephen, Hans Kreder, Richard Jenkinson, Markku Nousiainen, Terry Axelrod, John Murnaghan, Diane Nam, Veronica Wadey, Albert Yee, Katrine Milner, Monica Kunz (**Sunnybrook Health Sciences Centre**); Emil H. Schemitsch, Henry Ahn, Jeremy A. Hall, Michael D. McKee, Daniel B. Whelan, Aaron Nauth, Milena R. Vicente, Lisa M. Wild, Ryan M. Khan, Jennifer T. Hidy (**St. Michael's Hospital**); Chad Coles, Ross Leighton, Michael Biddulph, David Johnston, Mark Glazebrook, David Alexander, Cathy Coady, Michael Dunbar, David Amirault, Michael Gross, William Oxner, Gerald Reardon, Glen Richardson, Andrew Trenholm, Ivan Wong, Kelly Trask, Shelley MacDonald, Gwen Dobbin (**Queen Elizabeth II Health Sciences Centre**); Ryan Bicknell, Jeff Yach, Davide Bardana, Gavin Wood, Mark Harrison, David Yen, Sue Lambert, Fiona Howells, Angela Ward (**Human Mobility Research Centre, Queen's University and Kingston General Hospital**); Paul Zalzal, Heather Brien, V. Naumetz, Brad Weening, Nicole Simunovic (**Oakville Trafalgar Memorial Hospital**); Eugene K. Wai, Steve Papp, Wade T. Gofton, Allen Liew, Stephen P. Kingwell, Garth Johnson, Joseph O'Neil, Darren M. Roffey, Vivian Borsella (**Ottawa Hospital**); Victoria Avram (**Juravinski Hospital and Cancer Centre**)

*United States:*

Todd M. Oliver, Vicki Jones (**Boone Hospital Center – Columbia Orthopaedic Group**); Clifford B. Jones, James R. Ringler, Terrence J. Endres, Samuel G. Agnew, Debra L. Sietsema, Jane E. Walker (**Orthopaedic Associates of Michigan**); Kyle J. Jeray, J. Scott Broderick, David R. Goetz, Thomas B. Pace, Thomas M. Schaller, Scott E. Porter, Stephanie L. Tanner, Rebecca G. Snider, Lauren A. Nastoff, Shea A. Bielby (**Greenville Hospital System**); Julie A. Switzer, Peter A. Cole, Sarah A. Anderson, Paul M. Lafferty, Mengnai Li, Thuan V. Ly, Scott B. Marston, Amy L. Foley, Sandy Vang, David M. Wright (**Regions Hospital-University of Minnesota**); Andrew J. Marcantonio, Michael S.H. Kain, Richard Iorio, Lawrence M. Specht, John F. Tilzey, Margaret J. Lobo, John S. Garfi (**Lahey Hospital & Medical Center**); Heather A. Vallier, Andrea Dolenc, Chalitha Robinson (**MetroHealth Medical Center**); Michael J. Prayson, Richard Laughlin, L. Joseph Rubino, Jedediah May, Geoffrey Ryan Rieser, Liz Dulaney-Cripe, Chris Gayton (**Miami Valley Hospital**); James Shaer, Tyson Schrickel, Barbara Hileman (**St. Elizabeth Health Center**); John T. Gorczyca, Jonathan M. Gross, Catherine A. Humphrey, Stephen Kates, Krista Noble, Allison W. McIntyre, Kaili Pecorella (**University of Rochester Medical Center**); Craig A. Davis, Stewart Weirnerman, Peter Weingarten, Philip Stull, Stephen Lindenbaum, Michael Hewitt, John Schwappach, Janell K. Baker, Tori Rutherford, Heike Newman, Shane Lieberman, Erin Finn, Kristin Robbins, Meghan Hurley, Lindsey Lyle, Khalis Mitchell, Kieran Browner, Erica Whatley, Krystal Payton, Christina Reeves (**Colorado Orthopedic Consultants**); Lisa K. Cannada, David Karges, Leslie Hill (**St. Louis University Hospital**); Samir Mehta, John Esterhai, Jaimo Ahn, Annamarie D. Horan, Kelly McGinnis, Christine A. Kaminski, Brynn N. Kowalski (**University of Pennsylvania**); Jonathan P. Keeve, Christopher G. Anderson, Michael D. McDonald, Jodi M. Hoffman (**Northwest Orthopaedic Specialists**); Ivan Tarkin, Peter Siska, Gary Gruen, Andrew Evans, Dana J. Farrell, James

Irrgang, Arlene Luther (**University of Pittsburgh Medical Center**); William W. Cross III, Joseph R. Cass, Stephen A. Sems, Michael E. Torchia, Tyson Scrabeck (**Mayo Clinic**); Mark Jenkins, Jules Dumais, Amanda W. Romero (**Texas Tech University Health Sciences Center – Lubbock**); Carlos A. Sagebien, Mark S. Butler, James T. Monica, Patricia Seuffert (**University Orthopaedic Associates, LLC**); Joseph R. Hsu, James Ficke, Michael Charlton, Matthew Napierala, Mary Fan (**US Army Institute of Surgical Research**); Paul Tornetta III, Chadi Tannoury, Hope Carlisle, Heather Silva (**Boston University Medical Center**); Michael Archdeacon, Ryan Finnan, Toan Le, John Wyrick, Shelley Hess (**UC Health/University of Cincinnati Medical Center**); Michael L. Brennan, Robert Probe, Evelyn Kile, Kelli Mills, Lydia Clipper, Michelle Yu, Katie Erwin (**Scott and White Memorial Hospital**); Daniel Horwitz, Kent Strohecker, Teresa K. Swenson (**Geisinger Medical Center**); Andrew H. Schmidt, Jerald R. Westberg (**Hennepin County Medical Center**); Kamran Aurang, Gary Zohman, Brett Peterson, Roger B. Huff (**Kaiser Permanente**); Joseph Baele, Timothy Weber, Matt Edison (**OrthoIndy**); Jessica McBeth (**Santa Clara Valley Medical Center**); Karl Shively, Janos P. Ertl, Brian Mullis, J. Andrew Parr, Ripley Worman, Valda Frizzell, Molly M. Moore, Erin Tobias, Emily Thomas (**Indiana University – Wishard Health Services**); Charles J. DePaolo, Rachel Alosky, Leslie E. Shell, Lynne Hampton, Stephanie Shepard, Tracy Nanney, Claudine Cuento (**Mission Hospital Research Institute**); Robert V. Cantu, Eric R. Henderson, Linda S. Eickhoff (**Dartmouth-Hitchcock Medical Center**); E. Mark Hammerberg, Philip Stahel, David Hak, Cyril Mauffrey, Douglas Gibula, Hannah Gissel, Corey Henderson (**Denver Health and Hospital Authority**); David P. Zamorano, Martin C. Tynan, Deeba Pourmand, Deanna Lawson (**University of California Irvine Medical Center**); Gregory J. Della Rocca, Brett D. Crist, Yvonne M. Murtha, Linda K. Anderson (**University of Missouri Health Care**); Colleen Linehan, Lindsey Pilling (**Covenant Healthcare of Saginaw**); Courtland G. Lewis,

Stephanie Caminiti, Raymond J. Sullivan, Elizabeth Roper (**Hartford Hospital**); William Obremskey, Philip Kregor, Justin E. Richards, Kenya Stringfellow (**Vanderbilt University Medical Center**); Michael P. Dohm, Abby Zellar (**Western Slope Study Group**)

*The Netherlands:*

Michiel J.M. Segers, Jacco A.C. Zijl, Bart Verhoeven, Anke B. Smits, Jean Paul P.M. de Vries, Bram Fioole, Henk van der Hoeven, Evert B.M. Theunissen, Tammo S. de Vries Reilingh, Lonneke Govaert, Philippe Wittich, Maurits de Brauw, Jan Wille, Peter M.N.Y.M. Go, Ewan D. Ritchie, Ronald N. Wessel, Eric R. Hammacher (**St. Antonius Ziekenhuis**); Martin J. Heetveld, Gijs A. Visser, Heyn Stockmann, Rob Silvis, Jaap P. Snellen, Bram Rijbroek, Joris J.G. Scheepers, Erik G.J. Vermeulen, Michiel P.C. Siroen, Ronald Vuylsteke, Hans L.F. Brom, Herman Rijna (**Kennemer Gasthuis**); Piet A.R. de Rijcke, Cees L. Koppert, Steven E. Buijk, Richard P.R. Groenendijk, Imro Dawson, Geert W.M. Tetteroo, Milko M.M. Bruijninx, Pascal G. Doornebosch, Eelco J.R. de Graaf (**IJsselland Ziekenhuis**); Maarten van der Elst, Carmen C. van der Pol, Martijne van 't Riet, Tom M. Karsten, Mark R. de Vries, Laurents P.S. Stassen, Niels W.L. Schep, G. Ben Schmidt, W.H. Hoffman (**Reinier de Graaf Gasthuis**); Rudolf W. Poolman, Maarten P. Simons, Frank H.W.M. van der Heijden, W. Jaap Willems, Frank R.A.J. de Meulemeester, Cor P. van der Hart, Kahn Turckan, Sebastiaan Festen, Frank de Nies, Robert Haverlag, Nico J.M. Out, Jan Bosma (**Onze Lieve Vrouwe Gasthuis**); Albert van Kampen, Jan Biert, Arie B. van Vugt, Michael J.R. Edwards, Taco J. Blokhuis, Jan Paul M. Frölke, Leo M.G. Geeraedts, Jean W.M. Gardeniers, Edward T.C.H. Tan, Lodewijk M.S.J. Poelhekke, Maarten C. de Waal Malefijt, Bart Schreurs (**University Medical Center St. Radboud**); Gert R Roukema, Hong A. Josaputra, Paul Keller, Peter D. de Rooij, Hans Kuiken, Han Boxma, Berry I. Cleffken, Ronald Liem (**Maasstad Ziekenhuis**); Steven J. Rhemrev, Coks H.R. Bosman, Alexander de Mol van Otterloo,

Jochem Hoogendoorn, Alexander C. de Vries, Sven A.G. Meylaerts (**Medisch Centrum Haaglanden**); Michiel H.J. Verhofstad, Joost Meijer, Teun van Egmond, Frank H.W.M. van der Heijden, Igor van der Brand (**St. Elisabeth Ziekenhuis**); Peter Patka, Martin G. Eversdijk, Rolf Peters, Dennis Den Hartog, Oscar J.F. Van Waes, Pim Oprel (**Erasmus MC, University Medical Center Rotterdam**); Harm M van der Vis, Martin Campo, Ronald Verhagen, G.H. Robert Albers, Arthur W. Zurcher (**Tergooi Ziekenhuizen**); Rogier K.J. Simmermacher, Jeroen van Mulken, Karlijn van Wessem, Taco J. Blokhuis, Steven M. van Gaalen, Luke P.H. Leenen (**University Medical Center Utrecht**); Maarten W.G.A. Bronkhorst, Onno R. Guicherit (**Bronovo Ziekenhuis**); J. Carel Goslings, Robert Haverlag, Kees Jan Ponsen (**Academic Medical Center**)

*International:*

Mahesh Bhatia, Vinod Arora, Vivek Tyagi (**RLB Hospital and Research Centre, India**); Susan Liew, Harvinder Bedi, Ashley Carr, Hamish Curry, Andrew Chia, Steve Csongvay, Craig Donohue, Stephen Doig, Elton Edwards, Greg Etherington, Max Esser, Andrew Gong, Arvind Jain, Doug Li, Russell Miller, Ash Moaveni, Matthias Russ, Lu Ton, Otis Wang, Adam Dowrick, Zoe Murdoch, Claire Sage (**The Alfred, Australia**); Frede Frihagen, John Clarke-Jenssen, Geir Hjorthaug, Torben Ianssen, Asgeir Amundsen, Jan Egil Brattgjerd, Tor Borch, Berthe Bøe, Bernhard Flatøy, Sondre Hasselund, Knut Jørgen Haug, Kim Hemlock, Tor Magne Hoseth, Geir Jomaas, Thomas Kibsgård, Tarjei Lona, Gilbert Moatshe, Oliver Müller, Marius Molund, Tor Nicolaisen, Fredrik Nilsen, Jonas Rydinge, Morten Smedsrud, Are Stødle, Axel Trommer, Stein Ugland, Anders Karlsten, Guri Ekås, Elise Berg Vesterhus, Anne Christine Brekke (**Oslo University Hospital, Norway**); Ajay Gupta, Neeraj Jain, Farah Khan (**Nirmal Hospital, India**); Ateet Sharma, Amir Sanghavi, Mittal Trivedi (**Satellite Orthopaedic Hospital and Research Centre, India**); Anil Rai, Subash, Kamal

Rai (**Highway Hospital, India**); Vineet Yadav, Sanjay Singh, Kamal Rai (**Popular Hospital, India**); *Kevin Tetsworth*, Geoff Donald, Patrick Weinrauch, Paul Pincus, Steven Yang, Brett Halliday, Trevor Gervais, Michael Holt, Annette Flynn (**Royal Brisbane and Women's Hospital, Australia**); Amal Shankar Prasad, Vimlesh Mishra (**Madhuraj Nursing Home, India**); D.C. Sundaresh, Angshuman Khanna (**M.S. Rammaiah Medical College & Hospital, India**); Joe Joseph Cherian, Davy J Olakkengil, Gaurav Sharma (**St John's Medical College Hospital, India**); *Marinis Pirpiris*, David Love, Andrew Bucknill, Richard J Farrugia (**Royal Melbourne Hospital, Australia**); Hans-Christoph Pape, Matthias Knobe, Roman Pfeifer (**University of Aachen Medical Center, Germany**); *Peter Hull, Sophie Lewis, Simone Evans* (*Cambridge University Hospitals, England*); Rajesh Nanda, Rajanikanth Logishetty, Sanjeev Anand, Carol Bowler (**University Hospital of North Tees, England**); Akhil Dadi, Naveen Palla, Utsav Ganguly (**Sunshine Hospital, India**); B. Sachidananda Rai, Janakiraman Rajakumar (**Unity Health Complex, India**); Andrew Jennings, Graham Chuter, Glynis Rose, Gillian Horner (**University Hospital of North Durham and Darlington Memorial Hospital, England**); Callum Clark, Kate Eke (**Wexham Park Hospital, England**); Mike Reed, Chris Herriott, Christine Dobb (**Northumbria Healthcare NHS Foundation Trust, England**)



## **Conflict of interests and source of funding**

Members of the research team received a grant from Fonds NutsOhra (grant number T-0602-43), The Netherlands Organization for Health Research and Development (ZonMw; grant number 171102008), Physicians' Services Incorporated Foundation (grant number 08-18), and Canadian Institutes of Health Research (grant number 177466). The funding agencies were not involved in the study design, data collection, data analysis, manuscript preparations or publication decisions for this manuscript.

## **Abstract**

**Objectives:** The effect of implant removal after internal fixation of a femoral neck fracture on physical functioning was analyzed. Characteristics of patients who had their implant removed were studied, as it is currently unknown in which type of patients implants are removed and what effect removal has on function.

**Design:** Secondary cohort study alongside a RCT.

**Setting:** Multicenter study in 14 hospitals.

**Patients and Intervention:** Patients who had their implant removed after internal fixation of a femoral neck fracture are compared with patients who did not.

**Main outcome measurements:** Patient characteristics and quality of life (Short Form-12 (SF-12), Western Ontario McMaster Osteoarthritis Index (WOMAC)) were compared.

Matched pairs were selected based on patient/fracture characteristics and pre-fracture physical functioning.

**Results:** Of 162 patients, 37 had their implant removed (23%). These patients were younger (median age 67 versus 72 years,  $P=0.024$ ) and more often independently ambulatory pre-fracture (100% versus 84%,  $P=0.008$ ) than patients who did not. They more often had evident implant back-out on X-rays (54% versus 34%,  $P=0.035$ ), possibly related to a higher rate of Pauwels 3 fractures (41% versus 22%,  $P=0.032$ ). In time, quality of life improved more in implant-removal patients (+2 versus -4 points SF-12 (physical component),  $P=0.024$ ; +9 versus 0 points WOMAC,  $P=0.019$ ).

**Conclusions:** Implant removal after internal fixation of a femoral neck fracture positively influenced quality of life. Implant-removal patients were younger and more often independently ambulatory pre-fracture, more often had a Pauwels 3 fracture, and an evident

implant back-out. Implant removal should be considered liberally for these patients if pain persists or functional recovery is unsatisfactory.

**Level of evidence: II**

**Keywords:** Femoral neck fracture, hip fracture, internal fixation, implant removal, patient functioning.

## Introduction

Internal fixation of femoral neck fractures can sometimes result in long-term physical limitations and pain, even if fractures have healed uneventfully.<sup>1</sup> These limitations can be caused by physical changes such as tissue damage, scarring, and loss of muscle strength due to the injury and surgical exposure, or femoral neck shortening due to impaction at the fracture site.<sup>1</sup> The implant can cause local irritation and functional impairment.<sup>2-4</sup> In some patients with persistent complaints the implant is therefore removed after fracture healing. The rate of implant removal after internal fixation of femoral neck fractures is unknown. Reported implant removal rates after internal fixation of fractures at various anatomical locations including the hip, ranges from 16% to 81%.<sup>5,6</sup>

Guidelines on when to remove implants do not exist, mainly due to a lack of evidence. Several surveys among surgeons have indicated that patient related factors (*e.g.*, local irritation, pain, (unexplained) complaints, or patients request), possible carcinogenic/toxic, or unknown systemic effects, and expected problems with later removal due to bony overgrowth are considered reasons for implant removal.<sup>2-4,7</sup> A greater risk of future fractures due to stress shielding may also be a reason.<sup>8,2,4</sup> General reasons not to remove implants could be the risk of tissue or nerve damage, or an adverse event (mainly wound infection or hematoma) associated with secondary surgery. The costs of a second surgery and rehabilitation period may also play a role. Two cohort studies have indicated that removal of implants, at various anatomical locations, improves pain relief and function.<sup>9,10</sup> In other studies, however, the relief of complaints was not found.<sup>11,2,7</sup>

To the best of our knowledge, implant removal after internal fixation of femoral neck fractures has not been reported in detail. The effect of implant removal on physical functioning in these patients is therefore unknown. It is also unknown which patients are

candidates for removal. Therefore, the aim of this study was to analyze the effect of implant removal after internal fixation of a femoral neck fracture on physical functioning.

Characteristics of patients who had their implant removed were also described.

## **Patients and Methods**

### *Population*

This study was a secondary cohort study to the Dutch sample of an international randomized controlled trial, the FAITH trial (Fixation using Alternative Implants for the Treatment of Hip fractures, NCT00761813).<sup>12</sup> The primary objective of the FAITH trial was to assess the impact of internal fixation implants (sliding hip screw versus multiple cancellous screws) on rates of revision surgery at two years in elderly patients with femoral neck fractures (*i.e.*, AO type 31-B fractures).<sup>13</sup> In the Netherlands 14 hospitals participated and randomized 250 patients between February 2008 and August 2009. These patients were adults aged >50 years, who were ambulatory and not cognitively impaired pre-fracture. Patients had either (a) an undisplaced fracture, or (b) a displaced fracture in ASA 1-2 patients, who were 50-80 years old, with a fracture that could be reduced closed.<sup>14</sup> Surgeries were either performed or supervised by an experienced surgeon. All patients were allowed weight bearing as tolerated after surgery.

In the current study, all Dutch FAITH patients who healed after internal fixation were studied. Patients who had their implant removed were compared with patients who did not (control group). Patients who had a revision surgery due to implant failure, non-union, or avascular necrosis (*i.e.*, implant switch or salvage arthroplasty) were excluded. Patients who had a primary arthroplasty due to an unsuccessful fracture reduction were also excluded. The indication for implant removal was persisting pain and/or functional limitation in various degrees, which was considered to be (possibly) caused by the implant. The decision to remove the implant was left to the discretion of the treating surgeon. The implant was removed approximately one year after the fracture surgery if the fracture had healed.

### *Data and measurements*

Patient baseline characteristics, fracture characteristics, and follow-up data, including health-related quality of life (Short Form-12 (SF-12)) and disease-specific quality of life scores (Western Ontario McMaster Osteoarthritis Index (WOMAC)) were available from the FAITH trial.<sup>15,16</sup> In order to calculate the baseline (*i.e.*, pre-fracture) score, patients completed the questionnaires asking for their pre-fracture quality of life within one week after the fracture. SF-12 scores were converted to a norm-based score and compared with the norms for the general population of the United States (1998), as weighing factors for the Dutch population were not available.

X-rays were also collected. In order to study the relation between implant back-out and implant removal, a single investigator scored all X-rays for signs of 'evident implant back-out'. This was defined as back-out with evident increasing distance of the distal end of the implant in relation to the lateral femoral cortex (Figure 1).

### *Statistical analysis*

Analyses were performed using the Statistical Package for the Social Sciences (SPSS, version 16.0, SPSS Inc., Chicago, IL, USA). Baseline and fracture characteristics, as well as SF-12 and WOMAC scores at baseline (*i.e.*, pre-fracture) and after two years follow-up were compared. The change in scores between these two moments was calculated using the formula:  $\text{Change Score} = \text{Score}_{2 \text{ years}} - \text{Score}_{\text{baseline}}$ . Continuous data are presented as medians with percentiles, categorical variables as numbers and percentage. In the crude analysis, groups were compared using a Mann Whitney U-test (continuous data) or a Chi-squared test (categorical data).

In order to study the effect of implant removal on patient functioning more specifically, a matched pair analysis was performed. A matched control was searched for all

implant removal patients with complete follow-up data. Controls were considered adequate if they had a comparable age (<5 years difference), identical ASA score (American Society of Anesthesiologists classification), pre-fracture living status, pre-fracture use of ambulatory aids, fracture classification (Garden I/II versus III/IV and Pauwels 1-2 versus Pauwels 3), type of implant, and a comparable WOMAC score at baseline (<5 points difference). Use of a single control for multiple patients was allowed. In the matched pair analysis, SF-12 and WOMAC scores for the implant removal patients were calculated for the follow-up moment immediately before implant removal (mostly 12 or 18 months after initial fracture surgery) and at the first follow up moment after removal (mostly 18 or 24 months after initial fracture surgery). For the matched control the scores at the same follow-up moment in time were used. The change in scores between these two moments was calculated using the formula:  $\text{Change Score} = \text{Score}_{\text{after removal}} - \text{Score}_{\text{before removal}}$ . Groups were compared using a Wilcoxon signed rank test (continuous data). Results with  $P < 0.05$  (two-sided test) were regarded statistically significant.



## Results

### *Patient, fracture, and treatment characteristics*

Of the initial 250 patients, 162 patients healed uneventfully after internal fixation and were included. The remaining 88 patients were excluded, mainly since they had an arthroplasty as salvage procedure (N=69) or during primary surgery (N=16; Figure 2).

Patient, fracture, and treatment characteristics are shown in Table 1. Of the 162 patients who healed after internal fixation 37 patients had their implant removed (23%), at a median of 15 months after initial fracture surgery. Eight patients had an implant removal associated adverse event (22%); four patients sustained a bleeding or hematoma (11%), two patients a trochanteric bursitis (5%), one patient a urinary retention (3%), and one patient a wound infection (3%).

Patients who had their implant removed were significantly younger than patients who did not (median age 67 versus 72 years,  $P=0.024$ ) and significantly more often independent ambulatory pre-fracture (100% versus 84% independently ambulatory,  $P=0.008$ ). The implant removal patients also significantly more often had a Pauwels 3 type fracture (41% versus 22%,  $P=0.031$ ) and an evident implant back-out on X-rays (54% versus 34%,  $P=0.035$ ).

### *Crude analysis of patient self-reported health-related and disease-specific quality of life (SF-12 and WOMAC)*

At baseline (*i.e.*, pre-fracture) patients who had their implant removed had significantly higher SF-12 scores than patients who healed without implant removal (107 versus 102 points,  $P=0.038$ ). Especially the physical component summary scores were higher

(Supplemental Table 1). WOMAC scores were not significantly different at baseline (97 versus 95 points,  $P=0.101$ ).

After two years the SF-12 and WOMAC scores had decreased in patients who had their implant removed as well as in the patients who did not (Table 2). Again, this was mostly apparent in the physical component and function scores (Table 2). However, there was no significant difference in change between the groups; median change in SF-12 score -3 versus -3 points ( $P=0.700$ ) and WOMAC score -3 versus -4 points ( $P=0.427$ ; Table 2).

#### *Matched pair analysis*

Of the 37 implant removal patients, five patients could not be included in the matched pair analysis because they did not have complete follow-up data. A match could be found for 22 of the remaining patients (Figure 2). The matched pairs had similar characteristics, as expected (Table 1). The only difference was a higher percentage of patients with evident implant back-out in the implant removal group (50% versus 9%,  $P=0.004$ ).

At the follow-up moment directly before the implant removal (*i.e.*, mostly 12 or 18 months after initial fracture surgery), the implant removal patients reported significantly lower physical functioning scores than the patients who had their implant retained. This is reflected in the SF-12 physical component summary score (44 versus 53 points,  $P=0.005$ ) and all WOMAC sub-scores (pain 83 versus 100 points,  $P=0.001$ ; stiffness 75 versus 100 points,  $P=0.010$ ; function 82 versus 98 points,  $P=0.002$ ; Table 3). At the follow-up moment directly after the implant removal (*i.e.*, mostly 18 or 24 months after initial fracture surgery), only a significantly lower WOMAC pain sub-score in the implant removal group remained (90 versus 98 points,  $P=0.036$ ). Despite the second surgery and rehabilitation period, the implant removal patients still had an improvement of their physical functioning scores in the period of their implant removal, whereas the control group had not. This is reflected in an improvement

in SF-12 physical component summary score (2 versus -4 points,  $P=0.024$ ), WOMAC function sub-score (10 versus 0 points,  $P=0.030$ ) and WOMAC total score (9 versus 0 points,  $P=0.019$ ; Table 3).

## Discussion

Implant removal after internal fixation of a femoral neck fracture had a significantly positive effect on patient functioning. The functional outcome scores of both the SF-12 and the WOMAC improved significantly more in the patients who had their implant removed than in the patients who did not, in a similar time period. Even though the implant removal patients were significantly more impaired than the control group before implant removal, they had similar general health-related and disease-specific quality of life after two years follow-up, which could be related to the implant removal. This positive effect of implant removal is confirmed in other studies on implant removal for different fractures.<sup>9,10</sup> The positive effect of implant removal may in fact even have been underestimated, as quality of life measurements were sometimes performed shortly after the implant removal surgery (*i.e.*, <6 months). Patients could therefore still have been rehabilitating from the second surgery at the time of follow-up. This may also explain why the WOMAC pain sub-scores were not significantly different between the groups after implant removal, although P-values approximated the 0.05 significance threshold.

The current study again emphasizes that disease-specific quality of life scores (*e.g.*, WOMAC) seem more appropriate in hip fracture patients than general health-related quality of life scores (*e.g.*, SF-12). The problem in the hip fracture population is a complex assortment of issues ranging from baseline health and frailty, social isolation and support, mental status and joint function and pain, which are all expressed in general health-related quality of life. The change in physical functioning through time was better expressed in the WOMAC total and sub-scores, than in the SF-12 total and sub-scores (Table 3).

Patients who had their implant removed after internal fixation of a femoral neck fracture were significantly younger and more often independent ambulatory pre-fracture than

patients who did not. They also reported a better pre-fracture general health-related quality of life. This suggests that these patients were probably more mobile and active, and were therefore more impaired by the implant. Generally, it is likely that this patient category strived for a better outcome and performance level, and were less put off by the idea of a second surgery and rehabilitation period. In a previous study on implant removal after femur fractures, age also influenced the likelihood of removal.<sup>6</sup>

As expected, implant back-out was observed more often in patients who had their implant removed. Weight bearing can cause impaction at the fracture site and may result in femoral neck shortening, causing the implant to back-out.<sup>1</sup> The implant is then interfering with the surrounding soft tissues (*i.e.*, abductor muscles and fascia lata). This can result in pain and functional impairment, causing patients to have their implant removed. Apparently, implant back-out does not always cause complaints severe enough to decide on implant removal, as 34% of patients in the control group retained their implant despite an evident implant back-out. In 46% of patients, on the other hand, the implant was removed without signs of an evident implant back-out. Implant back-out is therefore not always the cause of complaints. Implant removal patients more often had a Pauwels 3 type fracture. A previous study already indicated a Pauwels 3 type fracture as risk factor for femoral neck shortening and therefore causing increased implant back-out.<sup>1</sup>

The reason for implant removal was pain and/or functional impairment in all patients. It was therefore expected that SF-12 and WOMAC scores before implant removal were significantly worse in the implant removal patients, as shown in the results.

Implant removal seems a safe procedure with minimal risk. None of the adverse events that occurred were severe or caused permanent disability. The argument of extra costs seems refutable in this population, as a previously published cost analysis of this study group indicated that the implant removal patients were actually less expensive than the patients who

healed without removal (€10,066 versus €17,405 after two years follow-up).<sup>14</sup> However, a selection bias may have played a role.

The main limitation of this study is the relatively low number of patients included, mainly in the matched pair analysis. If the study would be repeated with a higher number of patients and a longer period of follow-up after implant removal, it is likely that the positive effect of implant removal will even be more obvious. However, this is still the first study providing evidence on this topic, and significant effects are seen, even in this relatively small population. It would also be interesting to measure the effect on physical functioning using more objective parameters, such as gait parameters or muscle strength.<sup>1</sup> Unfortunately, our results can only prove a positive effect of implant removal for the patients who were selected in this study based on their symptoms and general condition. These patients were relatively young, healthy and independent pre-fracture. Results should therefore not be generalized.

In conclusion, implant removal after internal fixation of a femoral neck fracture had a significantly positive effect on patient functioning in this study. Patients who had their implant removed were younger, more often independently ambulatory pre-fracture, had a Pauwels 3 type fracture, and an evident implant back-out than patients who did not. Given the positive effects on patient functioning in this study, we suggest that implant removal should be considered more liberally in these patients, if there are persistent complaints of pain or unsatisfactory functional recovery after internal fixation of a femoral neck fracture.


## References

1. Zielinski SM, Keijsers NL, Praet SF et al. Femoral neck shortening after internal fixation of a femoral neck fracture. *Orthopedics*. 2013;36(7):e849-858.
2. Hanson B, van der Werken C, Stengel D. Surgeons' beliefs and perceptions about removal of orthopaedic implants. *BMC Musculoskelet Disord*. 2008;9:73.
3. Jamil W, Allami M, Choudhury MZ et al. Do orthopaedic surgeons need a policy on the removal of metalwork? A descriptive national survey of practicing surgeons in the United Kingdom. *Injury*. 2008;39(3):362-367.
4. Vos D, Hanson B, Verhofstad M. Implant removal of osteosynthesis: the Dutch practice. Results of a survey. *J Trauma Manag Outcomes*. 2012;6(1):6.
5. Bostman O, Pihlajamaki H. Routine implant removal after fracture surgery: a potentially reducible consumer of hospital resources in trauma units. *J Trauma*. 1996;41(5):846-849
6. Lovald S, Mercer D, Hanson J et al. Hardware removal after fracture fixation procedures in the femur. *J Trauma Acute Care Surg*. 2012;72(1):282-287.
7. Busam ML, Esther RJ, Obremsky WT. Hardware removal: indications and expectations. *J Am Acad Orthop Surg*. 2006;14(2):113-120.
8. Eberle S, Wutte C, Bauer C et al. Should extramedullary fixations for hip fractures be removed after bone union? *Clin Biomech*. 2011;26(4):410-414.
9. Minkowitz RB, Bhadsavle S, Walsh M et al. Removal of painful orthopaedic implants after fracture union. *J Bone Joint Surg Am*. 2007;89A(9):1906-1912.
10. Richards RH, Palmer JD, Clarke NM. Observations on removal of metal implants. *Injury*. 1992;23(1):25-28.


11. Brown OL, Dirschl DR, Obremskey WT. Incidence of hardware-related pain and its effect on functional outcomes after open reduction and internal fixation of ankle fractures. *J Orthop Trauma*. 2001;15(4):271-274.
12. FAITH investigators. Fixation using alternative implants for the treatment of hip fractures (FAITH): design and rationale for a multi-centre randomized trial comparing sliding hip screws and cancellous screws on revision surgery rates and quality of life in the treatment of femoral neck fractures. *BMC Musculoskelet Disord*. 2014;26(15):219.
13. Marsh JL, Slongo TF, Agel J, et al. Fracture and Dislocation Classification Compendium - 2007: Orthopaedic Trauma Association Classification, Database and Outcomes Committee. *J Orthop Trauma*. 2007;21 Supplement 10: S1-S133.
14. Zielinski SM, Bouwmans CA, Heetveld MJ et al. The societal costs of femoral neck fracture patients treated with internal fixation. *Osteoporos Int*. 2014;25(3):875-885.
15. Gandek B, Ware JE, Aaronson NK et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. *International Quality of Life Assessment*. *J Clin Epidemiol*. 1998;51(11):1171-1178.
16. Roorda LD, Jones CA, Waltz M et al. Satisfactory cross cultural equivalence of the Dutch WOMAC in patients with hip osteoarthritis waiting for arthroplasty. *Ann Rheum Dis*. 2004;63(1):36-42.



**Figure legends**



**Figure 1. Example of evident implant back-out**



**Figure 2. Flowchart of patients participating in this study**

## Tables

**Table 1. Patient characteristics**

|   | Crude analysis  |                  |         | Matched pair analysis |                  |         |
|---|-----------------|------------------|---------|-----------------------|------------------|---------|
|   | Implant removed | Implant retained | P-value | Implant removed       | Implant retained | P-value |
|   | (N=37)          | (N=125)          |         | (N=22)                | (N=22)           |         |
| Age (years) <sup>1*</sup>                         | 67 (60-73)      | 72 (62-79)       | 0.024   | 67 (61-74)            | 64 (60-72)       | 0.123   |
| BMI (kg/m <sup>2</sup> ) <sup>1</sup>             | 24 (21-26)      | 24 (22-26)       | 0.522   | 23 (20-26)            | 24 (21-28)       | 0.338   |
| ASA >2 <sup>2*</sup>                              | 2 (5)           | 21 (17)          | 0.088   | 0 (0)                 | 0 (0)            | 1.000   |
| Female <sup>2</sup>                               | 19 (51)         | 71 (57)          | 0.577   | 12 (55)               | 13 (59)          | 1.000   |
| Displaced fracture (Garden III-IV) <sup>2*</sup>  | 18 (49)         | 38 (30)          | 0.050   | 11 (50)               | 11 (50)          | 1.000   |
| Pauwels 3 fracture <sup>2*</sup>                  | 15 (41)         | 27 (22)          | 0.032   | 6 (27)                | 6 (27)           | 1.000   |
| Pre-fracture institutionalized <sup>2*</sup>      | 0 (0)           | 3 (2)            | 1.000   | 0 (0)                 | 0 (0)            | N.A.    |
| Pre-fracture independent ambulatory <sup>2*</sup> | 37 (100)        | 105 (84)         | 0.008   | 22 (100)              | 22 (100)         | N.A.    |
| Evident implant back-out <sup>2</sup>             | 20 (54)         | 41 (34)          | 0.035   | 11 (50)               | 2 (9)            | 0.004   |
| Time to implant removal (months) <sup>1</sup>     | 15 (13-17)      | N.A.             | N.A.    | 15 (13-17)            | N.A.             | N.A.    |

BMI, Body Mass Index; ASA, American Society of Anesthesiologists.

Differences between the groups were tested with the Mann Whitney U-test (crude analysis) or Wilcoxon signed rank test (matched pair analysis) for numeric variables, and the Chi-squared test (crude analysis) or McNemar's chi-squared test (matched pair analysis) for categorical variables.

<sup>1</sup> Data are presented as median with P<sub>25</sub>-P<sub>75</sub> given between brackets. <sup>2</sup> Data are presented as number with percentages.

\* This parameter was used to match pairs.

**Table 2. Changes in patient self-reported physical functioning after two years follow-up**

|                               | <b>Implant removed</b> | <b>Implant retained</b> | <b>P-value</b> |
|-------------------------------|------------------------|-------------------------|----------------|
|                               | <b>(N=37)</b>          | <b>(N=125)</b>          |                |
| <b>SF-12</b>                  |                        |                         |                |
| Change Score 2 years          | -3 (-19-4)             | -3 (-14-2)              | 0.700          |
| Change Physical (PCS) 2 years | -6 (-19- -1)           | -3 (-13-1)              | 0.167          |
| Change Mental (MCS) 2 years   | 3 (-4-9)               | 1 (-4-6)                | 0.368          |
| <b>WOMAC</b>                  |                        |                         |                |
| Change Score 2 years          | -3 (-32-0)             | -4 (-18-1)              | 0.427          |
| Change Pain 2 years           | -5 (-33-0)             | 0 (-10-0)               | 0.156          |
| Change Stiffness 2 years      | 0 (-38-0)              | 0 (-25-13)              | 0.086          |
| Change Function 2 years       | -4 (-35-0)             | -5 (-19-0)              | 0.676          |

SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS, Physical Component Summary; MCS, Mental Component Summary.

Scores were measured at baseline (*i.e.*, pre-fracture) and at two years later. These scores are presented in Supplemental table 1. The change in scores between these two moments was calculated using the formula: Change Score = Score<sub>2 years</sub> – Score<sub>baseline</sub>.

Data are presented as median with P<sub>25</sub>-P<sub>75</sub> given between brackets. Differences between the groups were tested with the Mann Whitney U-test.

1 **Table 3. Effect of implant removal on patient self-reported physical functioning**

|                               | <b>Implant removed</b> | <b>Implant retained</b> | <b>P-value</b> |
|-------------------------------|------------------------|-------------------------|----------------|
|                               | <b>(N=22)</b>          | <b>(N=22)</b>           |                |
| <b>SF-12</b>                  |                        |                         |                |
| Score before removal          | 99 (87-109)            | 107 (98-110)            | 0.062          |
| Physical (PCS) before removal | 44 (35-49)             | 53 (46-56)              | 0.005          |
| Mental (MCS) before removal   | 57 (48-62)             | 53 (50-61)              | 0.910          |
| Score after removal           | 104 (92-109)           | 107 (98-109)            | 0.236          |
| Physical (PCS) after removal  | 48 (42-51)             | 49 (43-52)              | 0.548          |
| Mental (MCS) after removal    | 56 (48-61)             | 59 (56-62)              | 0.050          |
| Change Score                  | 0 (-4-10)              | 0 (-2-4)                | 0.485          |
| Change Physical (PCS)         | 2 (-4-14)              | -4 (-7-0)               | 0.024          |
| Change Mental (MCS)           | 0 (-6-4)               | 4 (0-6)                 | 0.168          |
| <b>WOMAC</b>                  |                        |                         |                |
| Score before removal          | 82 (62-88)             | 98 (88-100)             | 0.001          |
| Pain before removal           | 83 (69-90)             | 100 (95-100)            | 0.001          |
| Stiffness before removal      | 75 (50-91)             | 100 (75-100)            | 0.010          |
| Function before removal       | 82 (61-88)             | 98 (89-100)             | 0.002          |
| Score after removal           | 90 (74-98)             | 93 (87-100)             | 0.106          |
| Pain after removal            | 90 (69-100)            | 98 (90-100)             | 0.036          |
| Stiffness after removal       | 81 (75-100)            | 94 (88-100)             | 0.057          |
| Function after removal        | 91 (71-100)            | 95 (85-100)             | 0.145          |
| Change Score                  | 9 (-2-16)              | 0 (-7-2)                | 0.019          |
| Change Pain                   | 5 (-1-11)              | 0 (-1-1)                | 0.051          |
| Change Stiffness              | 6 (-3-38)              | 0 (-13-3)               | 0.176          |

|                 |            |          |       |
|-----------------|------------|----------|-------|
| Change Function | 10 (-2-18) | 0 (-6-3) | 0.030 |
|-----------------|------------|----------|-------|

2 SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS,  
3 Physical Component Summary; MCS, Mental Component Summary.  
4 Scores were measured at the follow-up moment immediately before implant removal (mostly  
5 12 or 18 months after initial fracture surgery) and after removal (mostly 18 or 24 months after  
6 initial fracture surgery). For the matched control the same follow-up moment was used. The  
7 change in scores between these two moments was calculated using the formula: Change Score  
8 = Score<sub>after removal</sub> – Score<sub>before removal</sub>.  
9 Data are presented as median with P<sub>25</sub>-P<sub>75</sub> given between brackets. Differences between the  
10 groups were tested with the Wilcoxon signed rank test.

11 **Supplemental Table 1. Patient self-reported physical functioning at baseline and after 2 years follow-up**

|                         | <b>Total group /</b>   |                         |                | <b>Matched pair analysis</b> |                         |                |
|-------------------------|------------------------|-------------------------|----------------|------------------------------|-------------------------|----------------|
|                         | <b>Crude analysis</b>  |                         |                |                              |                         |                |
|                         | <b>Implant removed</b> | <b>Implant retained</b> | <b>P-value</b> | <b>Implant removed</b>       | <b>Implant retained</b> | <b>P-value</b> |
|                         | <b>(N=37)</b>          | <b>(N=125)</b>          |                | <b>(N=22)</b>                | <b>(N=22)</b>           |                |
| <b>SF-12</b>            |                        |                         |                |                              |                         |                |
| Score baseline          | 107 (99-114)           | 102 (92-110)            | 0.038          | 109 (100-114)                | 111 (100-114)           | 0.958          |
| Physical (PCS) baseline | 54 (48-57)             | 51 (43-55)              | 0.014          | 55 (49-58)                   | 54 (51-56)              | 0.741          |
| Mental (MCS) baseline   | 54 (48-59)             | 55 (48-59)              | 0.997          | 56 (51-59)                   | 54 (47-61)              | 0.715          |
| Score 2 years           | 106 (87-112)           | 98 (84-108)             | 0.219          | 106 (85-111)                 | 107 (97-113)            | 0.099          |
| Physical (PCS) 2 years  | 48 (36-52)             | 44 (33-52)              | 0.563          | 47 (37-52)                   | 52 (43-57)              | 0.046          |
| Mental (MCS) 2 years    | 58 (47-62)             | 55 (48-61)              | 0.296          | 58 (44-62)                   | 55 (54-62)              | 0.375          |
| Change Score            | -3 (-19-4)             | -3 (-14-2)              | 0.700          | -5 (-19-2)                   | -3 (-12-5)              | 0.149          |
| Change Physical (PCS)   | -6 (-19- -1)           | -3 (-13-1)              | 0.167          | -6 (-16- -1)                 | -2 (-12-2)              | 0.170          |
| Change Physical (MCS)   | 3 (-4-9)               | 1 (-4-6)                | 0.368          | 3 (-8-6)                     | 1 (-2-8)                | 0.274          |
| <b>WOMAC</b>            |                        |                         |                |                              |                         |                |



|                    |              |              |       |               |               |       |
|--------------------|--------------|--------------|-------|---------------|---------------|-------|
| Score baseline     | 97 (93-100)  | 95 (83-99)   | 0.101 | 98 (96-100)   | 98 (98-100)   | 0.063 |
| Pain baseline      | 100 (93-100) | 100 (90-100) | 0.838 | 100 (100-100) | 100 (100-100) | 0.276 |
| Stiffness baseline | 100 (88-100) | 88 (75-100)  | 0.091 | 100 (88-100)  | 100 (88-100)  | 0.593 |
| Function baseline  | 99 (93-100)  | 95 (81-100)  | 0.047 | 99 (96-100)   | 99 (98-100)   | 0.157 |
| Score 2 years      | 91 (65-96)   | 90 (72-97)   | 0.889 | 91 (65-96)    | 100 (91-100)  | 0.009 |
| Pain 2 years       | 95 (65-100)  | 95 (85-100)  | 0.189 | 95 (65-100)   | 100 (99-100)  | 0.009 |
| Stiffness 2 years  | 75 (56-100)  | 81 (63-100)  | 0.601 | 75 (50-100)   | 100 (88-100)  | 0.015 |
| Function 2 years   | 94 (65-98)   | 90 (67-97)   | 0.583 | 94 (65-97)    | 100 (91-100)  | 0.024 |
| Change Score       | -3 (-32-0)   | -4 (-18-1)   | 0.427 | -5 (-35- -2)  | 0 (-5-2)      | 0.009 |
| Change Pain        | -5 (-33-0)   | 0 (-10-0)    | 0.156 | -5 (-35-0)    | 0 (0-0)       | 0.034 |
| Change Stiffness   | 0 (-38-0)    | 0 (-25-13)   | 0.086 | -13 (-38-0)   | 0 (-13-13)    | 0.012 |
| Change Function    | -4 (-35-0)   | -5 (-19-0)   | 0.676 | -6 (-35- -1)  | 0 (-5-1)      | 0.023 |

12 SF-12, Short Form 12; WOMAC, Western Ontario McMaster Osteoarthritis Index; PCS, Physical Component Score; MCS, Mental Component  
13 Score. Scores were measured at baseline (*i.e.*, pre-fracture) and after 2 years follow-up. The change in scores between these two moments was  
14 calculated using the formula: Change Score = Score<sub>at 2 years</sub> – Score<sub>at baseline</sub>. Data are presented as median with P<sub>25</sub>-P<sub>75</sub> between brackets.  
15 Differences between the groups were tested with the Mann Whitney U-test (total group) or Wilcoxon signed rank test (matched pair analysis).